Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). Update March 2023

Rothschedl, E. and Wolf, S. (2022): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). Update March 2023. Fact Sheet Nr. 112.

[thumbnail of Fact Sheet Nr.112_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
128kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Fact Sheet Nr. 112
Deposited on:	03 Nov 2022 16:23
Last Modified:	06 Mar 2023 16:48

Repository Staff Only: item control page